Loading stock data…
$3.69+0.00 (+0.14%)
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Fulcrum Therapeutics, Inc. in the Healthcare sector is trading at $3.69 with a market capitalization of $285M. Wall Street consensus targets $3.67 (3 analysts), implying a -0.5% move over the next 12 months. The stock is currently near its 52-week low of $2.83, remaining 41.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$19.91M↑ | -$22.19M↑ | -$22.69M↓ | -$21.86M↓ | -$19.82M |
| Net Income | -$26.18M↓ | -$18.89M↑ | -$20.33M↓ | -$19.59M↓ | -$17.30M |
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage produ...